Unprecedented diversion-/abuse-resistance: molecular deactivation of opioid drugs
Ended Project Grant Awarded Last action
- Award ID
- R44DA037908
- Recipient
-
Elysium Therapeutics, Inc. UEI CQ2LJLATAKH9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,389,944
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- Oregon, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$151,553 | |
| Amendment | -$151,553 | |
| Amendment | $990,284 | |
| Amendment | $985,349 | |
| Amendment | $101,224 | |
| Amendment | -$101,224 | |
| Amendment | $986,904 | |
| Amendment | $355,366 | |
| Amendment | $5,000 | |
| Amendment | $1,145,409 | |
| Original award | $224,737 |
Show all 11
Quick answers
Who received award R44DA037908?
R44DA037908 was awarded to Elysium Therapeutics, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 15, 2014.
How much is award R44DA037908 worth?
$4,389,944 has been obligated on R44DA037908.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award